Glecirasib (JAB-21822) is a potent and selective covalent inhibitor targeting GDP-bound KRAS p.G12C and has shown impressive efficacy and tolerability in pivotal clinical trials in patients with KRAS p.G12C–mutated NSCLC (NCT06008288). This evidence concerns the gene KRAS and non-small cell lung carcinoma.